Glycovax Pharma launches a highly performant SLA Adjuvant

Developed through a licence from the National Research Council Canada (NRC)

MONTREAL, Quebec, Canada (date) – Glycovax Pharma Inc. is taking an important step forward in its contribution to the vaccine industry with the large-scale production of SLA, a new glycolipidic vaccine adjuvant developed by the National Research Council Canada (NRC). This NRC license represents a major strategic development for Glycovax Pharma to commercialize this unique adjuvant and meet the growing global demand for more effective vaccine solutions.
Vaccine adjuvants play a fundamental role in increasing the effectiveness of vaccines. Despite their importance, there are very few effective and versatile adjuvants that are registered and available globally. After more than 20 years of research and development, the SLA adjuvant has demonstrated a unique ability to significantly strengthen the immune response against a wide range of antigens, by increasing the intensity, quality or duration of the response.
This new adjuvant, developed from ancestral microorganisms, stands out for its versatility, thermal stability and safety, making it particularly suitable for large-scale production to meet the adjuvant needs of multiple vaccine developers worldwide. Glycovax has optimized SLA manufacturing in view of meeting strict Good Manufacturing Practices (GMP) standards to ensure consistent quality and global availability.
“The license with the NRC and our ability to produce SLA at scale marks a strategic step forward for Glycovax and for the vaccine industry,” said Dany Valiquette, President of Glycovax Pharma. “SLA represents a true game-changer for vaccine development, offering a powerful and versatile solution to improve the efficacy of existing vaccines and support next-generation vaccines. We are proud to be able to make this innovative technology available to vaccine developers around the world.”